Ignacio
Matos García
Consultor Médico
Gustave Roussy Cancer Campus
Villejuif, FranciaPublicaciones en colaboración con investigadores/as de Gustave Roussy Cancer Campus (2)
2021
-
Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study
The Lancet Respiratory Medicine, Vol. 9, Núm. 6, pp. 613-621
2020
-
Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors
Annals of Oncology, Vol. 31, Núm. 10, pp. 1405-1412